Sphingosylphosphocholine (SPC) is the deacylated derivative of sphingomyelin known to accumulate in neuropathic Niemann-Pick disease type A. SPC is a potent mitogen that increases intracellular free Ca2+ and free arachidonate through pathways that are only partly protein kinase C-dependent. Here we show that SPC increased specific DNA-binding activity of transcription activator AP-1 in electrophoretic mobility-shift assays. Increased DNA-binding activity of AP-1 was detected after only 1-3 min, was maximal after 6 hr, and remained elevated at 12-24 hr. c-Fos was found to be a component of the AP-1 complex. Northern hybridization revealed an increase in c-fos transcripts after 30 min. Since the increase in AP-1 binding activity preceded the
after 6 hr, and remained elevated at 12-24 hr. c-Fos was found to be a component of the AP-1 complex. Northern hybridization revealed an increase in c-fos transcripts after 30 min. Since the increase in AP-1 binding activity preceded the increase in c-fos mRNA, posttranslational modifications may be important in mediating the early SPC-induced increases in AP-1 DNA-binding activity. Western analysis detected increases in nuclear c-Jun and c-Fos proteins following SPC treatment. SPC also transactivated a reporter gene construct through the AP-1 recognition site, indicating that SPC can regulate the expression of target genes. Thus, SPC-induced cell proliferation may result from activation of AP-1, linking signal transduction by SPC to gene expression. Since the expression of many proteins with diverse functions is known to be regulated by AP-1, SPC-induced activation of AP-1 may contribute to the pathophysiology of Niemann-Pick disease.
In some forms of sphingolipidoses, disorders of sphingolipid catabolism, lyso derivatives of the parent sphingolipids are known to accumulate (1-3). Sphinogosylphosphocholine (SPC), the N-deacylated derivative of sphingomyelin, has been reported to be significantly increased (up to 40-fold) in spleen, liver, and brain of patients with Niemann-Pick type A (1A) disease who have sphingomyelinase deficiency, hepatosplenomegaly, and brain dysfunction (2-4). It has been suggested that SPC may contribute to the pathophysiology of this disease by deleteriously affecting mitochondrial function and Ca2+ uptake (2,4). SPC has other diverse biological effects which could be involved in the pathophysiology of Niemann-Pick type A disease. In mouse neuroblastoma cells, SPC induces neurite outgrowth (5, 6) . SPC is also an extremely potent mitogen in numerous cell types (7). In Swiss 3T3 fibroblasts, the mitogenic signaling pathways of SPC were found to be both protein kinase C-dependent and -independent, and SPC did not increase levels of sphingosine-1-phosphate (SPP), phosphatidate, inositol phosphate, or cAMP but did stimulate arachidonate release (7, 8) . SPC induced Ca2+ release from internal stores via a ligand-gated and voltage-modulated channel with unique pharmacologic and electrophysiologic properties in permeabilized leukemia cells (9) and mobilized Ca2+ from internal sources in other cell types, including fibroblasts (7,
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9-14). Finally, SPC has been found to stimulate a kinase that may be related to casein kinase 11 (15, 16) .
The nuclear events that follow these early events regulated by SPC are not known. We examined the role of the transcription factor AP-1 because AP-1 proteins bind to regulatory AP-1 consensus sequences of numerous genes involved in many long-term cellular responses, including DNA synthesis (17). We found that SPC stimulated DNA-binding activity of AP-1 and transactivated a reporter gene containing AP-1 recognition sites.t
EXPERIMENTAL PROCEDURES
Lipids. SPC (Matreya, Pleasant Gap, PA) was produced by acid hydrolysis of sphingomyelin and has been reported to be a 72:28 D-erythro/L-threo mixture (18). Methanolic SPC solutions were dried under N2, and the residue was dissolved in 0.4% bovine serum albumin (BSA; Sigma) by sonication.
Cell Culture. Swiss 3T3 fibroblasts (CCL 92; American Type Culture Collection) were cultured in 150-cm2 plastic Petri dishes, refed every 3 days until 90% confluent, and then refed and used 5 days later when quiescent (19). Prior to treatment, medium was aspirated and replaced with 10 ml of Dulbecco's modified Eagle's medium plus transferrin (5 ,ug/ml) and BSA (20 ,ug/ml) for at least 6 hr. Cells were generally treated with vehicle (BSA) or with 10 ,M SPC, a mitogenic, noncytotoxic concentration (11).
Electrophoretic Mobility-Shift Assay (EMSA). Nuclear extract was prepared as described (20) . Protein was determined with a Coomassie Plus kit (Pierce). Nuclear extract (5 ,ug) was incubated with poly(dI-dC) (1 ,ug; Pharmacia/LKB) and double-stranded 32P-labeled consensus oligonucleotide probe (0.3 ng, 2 x 106 cpm) with or without oligonucleotide competitors or antibodies (20) . Probes were 5'-end-labeled with [y-32P]ATP (Amersham) by T4 polynucleotide kinase (New England Biolabs) and purified with Sephadex G-50 spin columns (Pharmacia). DNA-protein complexes were resolved in 0.8-mm, 6% polyacrylamide gels (acrylamide/N,N'-methylenebisacrylamide weight ratio, 60:1) containing 0.5 x TBE (1 x TBE is 90 mM Tris/90 mM boric acid/2 mM EDTA) at 200 V for 1 hr at 25°C, autoradiographed, and quantified by scanning.
Figures show autoradiographs representative of two to three experiments.
Oligonucleotides and Antibodies. Oligonucleotides and sonicated salmon sperm DNA were from Stratagene. The AP-1 oligonucleotide contained an AP-1 consensus sequence (underlined) and an artificial arrangement of neighboring seAbbreviations: BSA, bovine serum albumin; EMSA, electrophoretic mobility-shift assay; SPC, sphingosylphosphocholine; SPP, sphingosine-1-phosphate; TPA, "12-0-tetradecanoylphorbol 13-acetate" (phorbol 12-myristate 13-acetate). *To whom reprint requests should be addressed. (Fig. 1A) . There was a lesser reduction with 10-fold excesses of unlabeled probes containing either a T -* G mutation in the first base of the AP-1 consensus sequence or an A -> C mutation in the last base of the consensus sequence, further demonstrating binding specificity (data not shown). DNAbinding activity of AP-1 was stimulated extremely rapidly, increasing significantly after only 1-3 min (Fig. 1B) . Addition of SPC directly to nuclear extract did not affect AP-1 DNAbinding activity (data not shown). Binding activity was maximal after 6 hr (18-fold) and remained elevated for 12-24 hr. After 1-3 hr of treatment with SPC, the induction was equivalent to that achieved with 10% calf serum (8-to 10-fold). Vehicle-treated controls did not show any stimulation in AP-1 DNA-binding activity and levels were constant over a period of many hours.
Protein Components of the AP-1 Complex. Preincubation of nuclear extract with c-Fos antibody 1 produced a supershifted band in EMSA, whereas preincubation with c-Fos antibody 2 eliminated binding ( Fig. 2A) . These results suggest that c-Fos was present in the complex. Although c-Fos antibody 1 is directed against a region of the DNA-binding domain of c-Fos, it is very well established that this antibody produces a specific supershifted band when added to the AP-1 complex induced in many cell types (20, 22 (50 ,ug) 
from these cells and from HeLa cells were immunoblotted with c-Jun polyclonal antibody (A) or c-Fos antibody 1 (B). Arrows, positions of prestained markers (kDa).
c-fos mRNA (Fig. 2B) , which then rapidly decreased and returned to basal levels by 2 hr. SPC was not as potent as 10% serum in increasing c-fos mRNA after 30 min (Fig. 2B) .
,
Western analysis with c-Jun antibody detected a major band with the same mobility as the 40-kDa human recombinant Jun protein (Fig. 3A) . Relative to unstimulated cells, Jun was increased in cells treated with SPC for 24 hr, or with serum for 1 hr, but not in cells treated with SPC for 10 min or 1 hr. For comparative purposes, we evaluated the effects of SPP, which is structurally similar to SPC but lacks the choline esterified to the 1-phosphate group. In cells treated with SPP for 21 hr, m l there was an increase in the 40-kDa c-Jun species, as well as in a species of -48 kDa (Fig. 3A) . HeLa cells grown in 10% calf serum were included to evaluate cell type-specific differences. As previously reported (25), the two immunopositive c-Jun (Fig. 3B) . (Fig. 4A4 ). DNA-binding activity of AP-3 was increased following 1 hr of serum treatment but minimally affected by SPC (Fig. 4B) . Reduction in binding with 10-fold and 50-fold molar excesses of unlabeled AP-2 and AP-3 probes confirmed binding specificity (Fig. 4C ).
DISCUSSION
Previous work has shown that SPC is a potent mitogen for various cells, including 3T3 fibroblasts (7). SPC alone was much more mitogenic than other known growth factors, such as insulin and epidermal growth factor. The mitogenic effect of SPC appeared to be very specific, since SPC was more potent than other lysophospholipids and structurally related sphingolipids examined (including ceramide, sphingosine, and SPP) (7). Similarly, in EMSAs and transfection assays, activity of SPC was reduced by N-acetylation and by dehydrogenation of the 4E double bond (data not shown). It is unlikely that SPC activates AP-1 binding activity via metabolism to other products, since exogenous SPC is readily taken up by cells and metabolized slowly after uptake in Swiss 3T3 fibroblasts (7).
The marked elevation in AP-1 DNA-binding activity within 1-3 min after SPC stimulation, the rapid increase of c-fos --mRNA levels (30 min), the sustained elevation of AP (27) and by malignant cell transformation when expression of these proteins (including Fra-1) is deregulated (28).
Posttranslational changes, such as phosphorylation of AP-1, are known to affect the stability and conformation of the dimer complex and to influence DNA-binding activity and transcriptional activation of . Jun (29, 30) and Fos (31) can be phosphorylated by various kinases at sites that both positively and negatively regulate transcriptional activity. Specific phosphatases may also regulate AP-1 activity by dephosphorylation near the carboxyl terminus (32).
Several lines of evidence suggest that such posttranslational changes may be involved in the activation of AP-1 by SPC. (i) SPC induced an increase in AP-1 DNA-binding activity after 1-3 min that preceded the increase in c-fos mRNA (observed only after 30 min). Consistent with this observation, pretreatment of cells with cycloheximide, an inhibitor of protein synthesis (33), for 10 min prior to the addition of SPC for 10 min to 3 hr, failed to inhibit the increase in SPC-induced AP-1 DNA-binding activity in EMSA. (ii) The lack of increase in c-Fos, Fra-1, and c-Jun levels detected by Western analysis in Swiss 3T3 fibroblasts treated with SPC for short times (10 min to 1 hr) could indicate that the enhanced AP-1 binding activity observed in EMSA at these times was due to posttranslational modifications (29). (iii) Anti-c-Fos, anti-c-Jun, and anti-Fra-1 antibodies detected proteins with different molecular masses after treatment with SPC, which could also have resulted from differential posttranslational phosphorylation of respective proteins (17, 22, 31, 34 
